efficacy of aterosclerosis of tofacitinib in rheumatoid arthritis

efficacy of aterosclerosis of tofacitinib in rheumatoid arthritis - efficacy of aterosclerosis of tofacitinib in rheumatoid arthritis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024143

Enrollment

Registered

2016-09-23

Start date

2015-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atherosclerosis efficacy of tofacitinib in RA

Interventions

RA patients with moderate to severe active disease despite MTX treatment (disease activity score: DAS28&gt

3.2)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: RA patients with moderate to severe active disease despite MTX treatment (disease activity score: DAS28>3.2)

Exclusion criteria

Exclusion criteria: NP

Design outcomes

Primary

Measure	Time frame
AS values in 54 weeks	—

Countries

Japan

Contacts

Public Contactkensuke kume

hiroshima clinic rheumatology

kumekensuke@live.jp082-232-0707

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026